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Abstract
Background: Metastasis is believed to progress in several steps including different pathways but
the determination and understanding of these mechanisms is still fragmentary. Microarray analysis
of gene expression patterns in breast tumors has been used to predict outcome in recent studies.
Besides classification of outcome, these global expression patterns may reflect biological
mechanisms involved in metastasis of breast cancer. Our purpose has been to investigate pathways
and transcription factors involved in metastasis by use of gene expression data sets.
Methods: We have analyzed 8 publicly available gene expression data sets. A global approach,
"gene set enrichment analysis" as well as an approach focusing on a subset of significantly differently
regulated genes, GenMAPP, has been applied to rank pathway gene sets according to differential
regulation in metastasizing tumors compared to non-metastasizing tumors. Meta-analysis has been
used to determine overrepresentation of pathways and transcription factors targets, concordant
deregulated in metastasizing breast tumors, in several data sets.
Results: The major findings are up-regulation of cell cycle pathways and a metabolic shift towards
glucose metabolism reflected in several pathways in metastasizing tumors. Growth factor pathways
seem to play dual roles; EGF and PDGF pathways are decreased, while VEGF and sex-hormone
pathways are increased in tumors that metastasize. Furthermore, migration, proteasome, immune
system, angiogenesis, DNA repair and several signal transduction pathways are associated to
metastasis. Finally several transcription factors e.g. E2F, NFY, and YY1 are identified as being
involved in metastasis.
Conclusion: By pathway meta-analysis many biological mechanisms beyond major characteristics
such as proliferation are identified. Transcription factor analysis identifies a number of key factors
that support central pathways. Several previously proposed treatment targets are identified and
several new pathways that may constitute new targets are identified.
Background
Breast cancer is the most common cancer among women
and the leading cause of cancer related death. Metastasis is
the main cause of death of the disease but the knowledge
of biological mechanisms in metastasis is still fragmen-
tary. Risk of recurrence is evaluated by clinical and patho-
logical criteria. However, the performance of this method
is far from optimal. Gene expression profiling of tumors
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eral studies with promising results for improvement of
risk prediction [1-9]. Despite these promising clinical
results, little insight to biological mechanisms has been
obtained from the large amount of gene expression data.
Pathway or gene ontology analyses in these studies are
limited to genes in the outcome classifier. The main mech-
anism observed is up regulation of cell cycle while other
pathways are more inconsistent between the studies[5,10-
12]. Another potential use of these data is to map deregu-
lation of transcription factors and miRNA having impact
on metastasis. If sufficient knowledge about sequence
motifs for these regulators existed, groups of genes with
common motifs might display concordant deregulation
in metastasizing tumors. An extensive knowledge of tran-
scription factor binding elements is gathered in TransFac
database http://www.gene-regulation.com and bioinfor-
matic prediction of target genes has been useful, while
prediction of miRNA target genes is still in its infancy [13].
However, systematic investigation with these methods in
prognostic gene expression data sets has not been per-
formed for breast cancer. The combined knowledge of
pathways and regulators of gene transcripts may deepen
the understanding of biological mechanisms in metasta-
sis.
Prognostic data set have been used for validation of prog-
nostic significance of gene sets e.g. representing a certain
pathway. For example Bild et al. developed cell models
representing candidate metastatic pathways, defined char-
acteristic gene sets by microarray gene expression analysis,
and demonstrated prognostic value in the prognostic data
sets performed with gene expression [14]. However, these
candidate pathways presumably only represent a fraction
and not necessarily the most important of the pathways
involved in metastasis. We hypothesize that many biolog-
ical pathways and transcriptional regulators are involved
in metastasis of breast cancer and that they are reflected in
gene expression patterns of primary tumors. Our aim is to
elucidate metastatic pathways and secondly transcrip-
tional regulators and to integrate the knowledge of these
informations.
Pathway analysis programs typically compare level of
gene expression in two sets of samples by ranking genes
according to a statistic model and apply a cut-off value for
genes resulting in a group of significantly up- and down-
regulated genes. Overrepresentation analysis then identi-
fies pathways significantly regulated in these groups. We
have supplemented this kind of analysis with a more glo-
bal approach by gene set enrichment analysis (GSEA), to
identify pathways that are differentially regulated in
metastasizing and non-metastasizing tumors. By this
method, the imbalance of pathway gene-sets is examined
in the entire list of ranked genes. In a single data set this
analysis will generally not result in significant findings
beyond major pathways like cell cycle. By performing
meta-analysis of 8 data sets, we have increased the power
to identify pathways and transcription factors involved in
metastasis of breast cancer.
Methods
Data sets
Eight publicly available data sets of gene expression at
RNA level in primary tumors were included in the analy-
sis. These studies are performed with different platforms,
different populations etc. as depicted in table 1. The out-
come differs in that local and regional recurrences are
included in some studies. However, non-metastatic
relapse constitute a minority in clinical cohorts. There
may be overlap in the samples in the different data set e.g.
samples from Uppsala in Sotiriou 2006 and Uppsala data
sets, but the total number of different tumor samples is at
least 1200.
The normalizations performed in the studies were
retained because the authors found these methods opti-
mal for the data sets, and because pathway analysis was
performed separately in each data set.
Gene set enrichment analysis of pathways, transcription 
factors and miRNA
GSEA v 2.0 [15] was used with 450 curated gene sets rep-
resenting individual pathways. These pathway gene sets
are adopted from KEGG http://www.genome.ad.jp/
KEGG, GenMapp http://www.genmapp.org, Biocarta
http://www.biocarta.com etc. and gathered in the Molec-
ular Signature Database implemented in GSEA. For the
analysis of promoter and miRNA response elements 837
sequence elements predicted or validated to bind tran-
scription factors or miRNA's were downloaded from
MsigDB. The motifs are collected from TransFac http://
www.gene-regulation.com and mirBase http://micro
rna.sanger.ac.uk and target gene sets defined by bioinfor-
matic prediction of target genes [13,15]. The GSEA pro-
gram ranks genes according to a signal-to-noise value:
(XA-XB)/(sA+sB), where X is the mean and s is the standard
deviation for the two classes A and B (metastases and non-
metastases). When several probes recognized the same
gene, the probe with max expression value was extracted
using the "collapse to gene set" function. Gene sets repre-
sented by less than 15 genes in a data set was excluded
except for the Sotiriou 2003 data set where this threshold
was set to 10 genes because of the low number of genes on
that chip.
The output from GSEA is an enrichment score, describing
the imbalance in the distribution of ranks of gene expres-
sion in each gene set between metastasizing and non-
metastasizing tumors. The enrichment score is normal-Page 2 of 12
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ranked according to the normalized enrichment score
with gene sets up-regulated in metastasizing tumors on
the top and down-regulated gene sets in the bottom.
GenMAPP pathway analysis
To perform pathway analysis with an independent
method, GenMapp 2.0 software was used, by applying a
significance cut-off for genes between metastasizing and
non-metastasizing tumors of p = 0.05 in Students T-test.
The software uses Fisher exact test to examine overrepre-
sentation of up-regulated or down-regulated genes among
203 pathways. The output is a ranked list of up-regulated
and down-regulated pathways respectively for each data
set.
Meta-analysis
The ranked lists of gene sets for each analysis generated by
GSEA or GenMAPP from the 8 data sets were integrated so
that only gene sets represented in output from all data sets
were included. The initial 450 pathway gene sets in
MSigDb for the GSEA pathway analysis were reduced to
223 gene sets passing the threshold (at least 10 or 15
genes in gene sets) in all data sets. For analysis of tran-
scription factor and miRNA binding sites, 837 motif gene
sets from MSigDb were reduced to 761 motif gene sets.
203 GenMAPP pathways were reduced to 177 pathways
present in all data sets. For each data set, individual gene
sets were assigned a ranking value from 1 to the maximum
number of gene sets, according to the ranking performed
by GSEA or GenMAPP. The mean ranking value for each
gene set was calculated across the data sets and finally the
gene sets were ranked according to this value.
Our null-hypothesis is that the expressions of genes in
pathway gene sets are unrelated to metastasis. This means
that the ranking value for a given gene set in a given data
set is expected to be a random value between 1 and the
maximum number of gene sets analyzed. To simulate the
distribution of mean ranking values across the 8 data sets
fulfilling the null-hypothesis, random drawing of 8 rank-
ing values were performed 106 times and the mean value
was calculated each time. A null distribution of mean
ranking values was generated from these results. To test
the significance for a given gene set, the observed mean
ranking value was compared to the null distribution. To
fulfill the null-hypothesis an observed mean ranking
value should be within 95% interval of the null-distribu-
tion. This calculation, estimation of p-value and correc-
tion of p-value by false discovery rate (FDR) was
Table 1: Characteristics of patients and platforms in included studies.
Data set chip # probes Patients, country, nodal statusa outcomeb Adjuvant systemic treatmentc
HUMAC [1] spotted
oligonucleotides
29K n = 60, DK
N-, low-malignant
metastasis nil
Huang [2] Affymetrix
95av2
12K n = 52, Taiwan
N+
relapse ct
Sotiriou 2003 [3] Spotted
cDNA
7.6K n = 99, UK
N+/N-
relapse et, ct
Sotiriou 2006 [4] Affymetrix
HG-133A
22K n = 179 S (Uppsala), UK
N+/N-
dm et
Rotterdam [5] Affymetrix
HG-133A
22K n = 286, NL
N-
dm nil
Amsterdam [6] Rosetta 25K n = 295, NL
N+/N-
dm nil, ct, et
Uppsala [7] Affymetrix
HG133A+B
44K N = 236, S (Uppsala)
N+/N-
death from breast 
cancer
nil, ct, et
Stockholm [8] Affymetrix
HG-133A+B
44K n = 159, S (Stockholm)
N+/N-
relapse nil, ct, et
a: n, number of patients included; N+, positive nodal status; N-, negative nodal status; DK, Denmark; UK, United Kingdom; NL, the Netherlands; S, 
Sweden.
b: dm, distant metastasis,
c: ct, chemotherapy, et: endocrine therapyPage 3 of 12
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tor.org. Gene sets with FDR values below 0.05 were con-
sidered significant.
Results
Pathway analysis
Data from more than 1200 breast cancer patients were
collected (table 1). GSEA only identified few significant
pathways within each data set (data not shown). How-
ever, by performing meta-analysis of gene sets ranked by
enrichment score, several gene sets turned out to have low
ranking number in the majority of data sets indicating up-
regulation of corresponding pathway in metastasizing
tumors compared to non-metastasizing tumors. Similar,
gene sets with a high mean ranking value indicated low
expression in metastasizing tumors compared to non-
metastasizing tumors (table 2). False discovery rates indi-
cated 38 of these gene sets to be significantly differentially
expressed; 26 up-regulated and 12 down-regulated. The
most striking pathways are DNA replication and cell cycle
that are both up-regulated.
An independent method, GenMAPP, with a very different
approach, including only the most significant genes, was
Table 2: Metastatic pathways identified by gene set enrichment meta-analysis.
Pathway Ams Hua HUM Rot S03 S06 Sto Upp mean p FDR
Up-regulated
DNA_REPLICATION_REACTOME 11 64 2 19 5 6 2 6 14.4 < 10E-6 < 10E-6
CELL_CYCLE_KEGG 4 101 1 14 39 5 3 12 22.4 1.0E-6 1.1E-4
ATRBRCAPATHWAY 58 10 23 1 73 41 9 17 29.0 2.2E-5 1.5E-3
AMINOACYL_TRNA_BIOSYNTHESIS 35 90 57 21 9 9 8 10 29.9 2.7E-5 1.5E-3
PYRIMIDINE_METABOLISM 5 9 11 20 159 3 7 34 31.0 3.5E-5 1.6E-3
G1_TO_S_CELL_CYCLE_REACTOME 22 141 5 5 65 19 5 11 34.1 8.2E-5 3.0E-3
PROTEASOME_DEGRADATION 29 128 71 29 2 13 1 7 35.0 1.0E-4 3.0E-3
G2PATHWAY 30 107 4 23 86 8 15 9 35.3 1.1E-4 3.0E-3
PROTEASOMEPATHWAY 36 155 45 10 1 14 10 16 35.9 1.3E-4 3.1E-3
PURINE_METABOLISM 23 70 54 38 57 22 22 28 39.3 2.7E-4 6.0E-3
MRNA_PROCESSING_REACTOME 59 67 68 34 14 53 23 20 42.3 5.0E-4 1.0E-2
PROTEASOME 38 171 18 31 3 50 12 26 43.6 6.6E-4 1.2E-2
VEGFPATHWAY 41 52 84 4 37 38 81 13 43.8 6.8E-4 1.2E-2
PENTOSE_PHOSPHATE_PATHWAY 28 140 83 68 10 17 4 3 44.1 7.3E-4 1.2E-2
CELLCYCLEPATHWAY 44 112 3 13 139 2 27 21 45.1 8.7E-4 1.3E-2
GLYCOLYSIS_AND_GLUCONEOGENESIS 1 145 107 62 4 10 16 24 46.1 1.1E-3 1.5E-2
OXIDATIVE_PHOSPHORYLATION 80 142 25 15 85 16 11 1 46.9 1.2E-3 1.6E-2
G1PATHWAY 75 39 27 11 171 25 36 8 49.0 1.7E-3 2.0E-2
ARAPPATHWAY 19 8 175 17 49 43 25 56 49.0 1.7E-3 2.0E-2
FRUCTOSE_AND_MANNOSE_METABOLISM 10 11 145 41 58 101 19 14 49.9 2.0E-3 2.3E-2
S1P_SIGNALING 17 35 60 25 131 66 51 22 50.9 2.4E-3 2.5E-2
ACTINYPATHWAY 6 219 50 2 15 60 24 43 52.4 3.0E-3 3.1E-2
ELECTRON_TRANSPORT_CHAIN 131 191 36 9 41 12 6 5 53.9 3.8E-3 3.7E-2
RNA_TRANSCRIPTION_REACTOME 133 69 6 24 97 49 37 19 54.3 4.0E-3 3.7E-2
MPRPATHWAY 26 176 12 28 129 1 20 44 54.5 4.2E-3 3.7E-2
UBIQUITIN_MEDIATED_PROTEOLYSIS 46 125 128 89 6 15 14 15 54.8 4.3E-3 3.7E-2
Down-regulated
HISTIDINE_METABOLISM 193 151 117 189 184 191 145 212 172.8 2.5E-3 4.6E-2
PPARAPATHWAY 192 167 131 177 168 133 206 210 173.0 2.4E-3 4.6E-2
GLYCEROLIPID_METABOLISM 165 85 204 207 221 185 155 177 174.9 1.8E-3 4.0E-2
FATTY_ACID_METABOLISM 164 210 176 138 200 140 163 211 175.3 1.7E-3 4.0E-2
PDGFPATHWAY 209 127 182 185 112 181 212 213 177.6 1.1E-3 3.1E-2
EGFPATHWAY 208 124 192 191 106 197 190 215 177.9 1.1E-3 3.1E-2
NUCLEAR_RECEPTORS 173 202 121 174 199 150 214 193 178.3 9.8E-4 3.1E-2
BETA_ALANINE_METABOLISM 218 164 116 165 218 163 193 203 180.0 7.2E-4 3.1E-2
TOLLPATHWAY 212 119 167 204 128 223 165 222 180.0 7.2E-4 3.1E-2
GPCRDB_OTHER 134 196 164 158 210 196 205 195 182.3 4.5E-4 3.1E-2
GLEEVECPATHWAY 219 73 177 219 203 166 199 219 184.4 2.9E-4 3.1E-2
VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 222 174 184 181 207 194 97 217 184.5 2.8E-4 3.1E-2
The ranking numbers indicate the ranking of each gene set (pathway) out of the 223 gene sets in each data set and the mean ranking number 
indicate the ranking in the meta-analysis. Only 38 significant out of a total of 223 gene sets are shown. Ams: Amsterdam, Hua: Huang, HUM: 
HUMAC, Rot: Rotterdam, S03: Sotiriou 2003, S06: Sotiriou 2006, Sto: Stockholm, Upp: Uppsala.Page 4 of 12
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ysis of up- and down-regulated gene sets are performed
independently, resulting in two ranked output lists, with
up- or down-regulated pathways on the top respectively.
For this reason up-regulated as well as down-regulated
pathways have low mean ranking numbers (table 3).
Eleven pathways are up-regulated and 8 are down-regu-
lated. Again cell cycle (KEGG and
G1_to_S_control_reactome) and DNA replication reac-
tome, but also electron transport chain, are strikingly up-
regulated.
Regulatory motifs
GSEA was also applied to gene sets having in common rec-
ognition elements for transcription factors within pro-
moter regions or miRNA recognition elements in 3'UTR's
(table 4). Gene sets with low mean ranking number and
FDR below 0.05 were interpreted as significantly up-regu-
lated and gene sets with high mean ranking number were
considered down-regulated. In this analysis it is striking
that all significant gene sets are up-regulated and E2F fam-
ily members are strongly overrepresented. Several differ-
ent gene sets predicted to be recognized by the same
transcription factor are included in the analysis because
different variants of binding motifs have been reported to
TransFac database. Elements with unknown transcription
factor are predicted by bioinformatic comparison of pro-
moter regions [13].
Discussion
We have performed meta-analysis of 8 publicly available
gene expression data sets to identify common biological
mechanisms involved in metastasis of breast cancer. The
identified pathways can be grouped into a limited
number of categories: cell cycle and proliferation, growth
factor pathways, metabolism, angiogenesis, gleevec,
migration, signal transduction, proteasome pathway,
immune system, and DNA damage sensing and repair,
which are discussed in section 1 below. Some of the path-
ways are supported by key transcription factors identified
by motif analysis. In section 2, the methods used for path-
way analysis and the advantage of meta-analysis are dis-
cussed.
1.1 Cell cycle and proliferation
Among the pathways most up-regulated in metastasizing
tumors, identified by GSEA, are cell cycle pathways repre-
sented by five cognate pathways (CELL_CYCLE_KEGG,
CELLCYCLEPATHWAY, G1PATHWAY,
G1_TO_S_CELL_REACTOME, and G2PATHWAY). This is
supported by GenMAPP analysis identifying two of these
pathways to be most differently regulated between metas-
tasizing and non-metastasizing tumors
(CELL_CYCLE_KEGG and G1_TO_S_CELL_ REAC-
TOME). Up-regulation of cell cycle and proliferation is a
hallmark of cancer cells compared to normal cells. Our
observation, that cell cycle genes are up-regulated in cells
Table 3: Pathways identified by GennMAPP analysis
Pathway Ams Hua HUM Rot S03 S06 Sto Upp mean p FDR
Up-regulated
Hs_Cell_cycle_KEGG 1 97 2 1 1 4 1 1 13.5 < 10E-6 9.0E-5
Hs_Cell_Cycle-G1_to_S_control_Reactome 3 51 21 13 5 7 8 11 14.9 < 10E-6 9.0E-5
Hs_DNA_replication_Reactome 2 124 3 8 6 10 2 3 19.8 5.0E-6 3.0E-4
Hs_Electron_Transport_Chain 73 9 34 2 35 11 4 2 21.3 1.0E-5 4.4E-4
Hs_Androgen-Receptor_NetPath_2 82 12 9 16 20 5 43 19 25.8 4.6E-5 1.3E-3
Hs_1-Tissue-Embryonic_Stem_Cell 6 157 1 4 22 3 13 4 26.3 5.2E-5 1.3E-3
Hs_mRNA_processing_Reactome 45 22 64 6 33 26 9 5 26.3 5.2E-5 1.3E-3
Hs_Citrate_cycle_TCA_cycle_ 18 23 81 40 7 35 11 21 29.5 1.5E-4 3.3E-3
Hs_Aminoacyl_tRNA_biosynthesis 19 101 84 32 10 13 3 8 33.8 4.7E-4 9.3E-3
Hs_Cholesterol_Biosynthesis 28 119 7 41 13 56 6 24 36.8 1.0E-3 1.8E-2
Hs_Hedgehog_Netpath_10 41 5 4 21 99 18 76 65 41.1 2.7E-3 4.3E-2
Down-regulated
Hs_Adipogenesis 4 22 41 43 16 58 2 1 23.4 2.5E-5 4.4E-3
Hs_EGFR1_NetPath_4 5 3 42 44 24 13 13 80 28.0 1.0E-4 8.9E-3
Hs_T-Cell-Receptor_NetPath_11 37 2 75 6 38 28 19 51 32.0 3.0E-4 1.8E-2
Hs_Smooth_muscle_contraction 30 51 36 23 34 50 12 44 35.0 6.6E-4 2.4E-2
Hs_Insulin_Signaling 15 11 54 64 39 47 16 39 35.6 7.7E-4 2.4E-2
Hs_IL-6_NetPath_18 16 8 163 3 41 7 26 23 35.9 8.1E-4 2.4E-2
Hs_IL-7_NetPath_19 7 5 141 9 19 15 28 78 37.75 1.3E-3 3.0E-2
Hs_IL-3_NetPath_15 58 7 56 18 32 29 44 61 38.125 1.4E-3 3.0E-2
The ranking numbers indicate the ranking of each gene set (pathway) out of the 177 gene sets in each data set and the mean ranking number 
indicate the ranking in the meta-analysis. Only 19 significant out of a total of 177 gene sets are shown. Ams: Amsterdam, Hua: Huang, HUM: 
HUMAC, Rot: Rotterdam, S03: Sotiriou 2003, S06: Sotiriou 2006, Sto: Stockholm, Upp: Uppsala.Page 5 of 12
(page number not for citation purposes)
BMC Cancer 2008, 8:394 http://www.biomedcentral.com/1471-2407/8/394
Page 6 of 12
(page number not for citation purposes)
Table 4: Gene set enrichment meta-analysis of transcriptional regulatory motifs
motif Ams Hua HUM Rot S03 S06 Sto Upp mean p FDR
V$E2F_Q6_01 2 165 13 75 2 11 16 25 38.6 < 10E-6 < 10E-6
V$E2F_03 3 273 15 25 7 13 13 9 44.8 < 10E-6 < 10E-6
V$E2F_Q4_01 7 235 17 65 4 20 6 16 46.3 < 10E-6 < 10E-6
KTGGYRSGAA_UNKNOWN 16 191 8 126 43 1 8 23 52.0 < 10E-6 < 10E-6
V$E2F_Q3 30 289 22 80 23 29 4 8 60.6 < 10E-6 < 10E-6
V$E2F1_Q4_01 18 501 18 12 51 24 14 4 80.3 3.0E-6 3.3E-4
V$E2F1_Q6_01 15 440 14 79 44 38 11 14 81.9 3.0E-6 3.3E-4
V$E2F_Q3_01 14 535 21 14 46 28 15 5 84.8 6.0E-6 5.3E-4
V$E2F_Q6 28 595 9 17 9 15 2 6 85.1 7.0E-6 5.3E-4
GCCATNTTG_V$YY1_Q6 89 87 254 60 27 117 39 29 87.8 7.0E-6 5.3E-4
V$E2F1_Q3 9 588 5 43 35 21 7 2 88.8 8.0E-6 5.5E-4
V$E2F_Q4 26 617 12 16 10 25 3 7 89.5 1.0E-5 6.3E-4
V$E2F1DP1RB_01 21 607 10 34 19 16 9 3 89.9 1.2E-5 7.0E-4
ACTWSNACTNY_UNKNOWN 218 32 142 151 90 63 10 48 94.3 1.5E-5 8.2E-4
GGAANCGGAANY_UNKNOWN 227 14 305 58 45 110 1 1 95.1 1.7E-5 8.6E-4
TCCCRNNRTGC_UNKNOWN 151 117 33 10 152 158 33 115 96.1 1.8E-5 8.6E-4
V$NFY_Q6 84 74 36 272 151 76 25 66 98.0 2.2E-5 9.8E-4
V$E2F1_Q6 32 649 6 36 21 12 12 19 98.4 2.5E-5 1.1E-3
V$E2F4DP1_01 31 672 7 23 13 19 18 15 99.8 3.0E-5 1.1E-3
SGCGSSAAA_V$E2F1DP2_01 4 698 11 26 12 17 17 18 100.4 3.0E-5 1.1E-3
V$E2F1DP2_01 11 695 1 44 15 6 21 11 100.5 3.1E-5 1.1E-3
V$E2F1DP1_01 12 694 2 45 16 7 22 12 101.3 3.2E-5 1.1E-3
V$E2F4DP2_01 13 693 3 46 17 8 23 13 102.0 3.5E-5 1.1E-3
V$E2F_02 24 685 4 48 18 10 20 10 102.4 3.5E-5 1.1E-3
TGASTMAGC_V$NFE2_01 19 166 301 152 6 23 83 87 104.6 4.1E-5 1.2E-3
AACYNNNNTTCCS_UNKNOWN 77 9 299 216 22 101 52 77 106.6 4.6E-5 1.3E-3
V$NRF1_Q6 38 224 114 233 8 150 51 42 107.5 4.7E-5 1.3E-3
V$ELK1_02 198 219 160 32 194 56 27 26 114.0 7.7E-5 2.1E-3
V$E2F1_Q4 25 511 39 98 96 85 26 45 115.6 9.1E-5 2.4E-3
GCGSCMNTTT_UNKNOWN 208 56 37 396 37 161 48 49 124.0 1.8E-4 4.4E-3
V$GABP_B 36 22 173 562 86 107 5 17 126.0 2.1E-4 5.0E-3
V$YY1_Q6 216 215 304 87 26 81 58 59 130.8 2.8E-4 6.5E-3
V$USF2_Q6 172 207 82 328 113 53 57 53 133.1 3.2E-4 7.4E-3
V$NRF2_01 301 19 383 64 103 127 74 39 138.8 4.6E-4 1.0E-2
V$E2F_01 20 641 16 222 172 3 19 21 139.3 4.7E-4 1.0E-2
V$SP1_Q6_01 23 18 310 545 29 102 35 61 140.4 4.9E-4 1.0E-2
V$ARNT_02 221 248 68 169 76 222 38 86 141.0 5.1E-4 1.0E-2
V$HIF1_Q5 62 279 168 159 285 69 71 38 141.4 5.2E-4 1.0E-2
RACTNNRTTTNC_UNKNOWN 315 6 279 119 211 82 94 27 141.6 5.3E-4 1.0E-2
V$BACH1_01 17 118 349 187 133 44 63 239 143.8 6.2E-4 1.2E-2
ATCMNTCCGY_UNKNOWN 40 428 56 51 321 14 133 113 144.5 6.4E-4 1.2E-2
V$AP1_01 51 85 177 287 42 43 120 361 145.8 6.9E-4 1.2E-2
ACTAYRNNNCCCR_UNKNOWN 171 13 83 66 637 109 29 72 147.5 7.5E-4 1.3E-2
V$ER_Q6_02 118 366 63 176 177 214 37 58 151.1 9.4E-4 1.6E-2
V$CETS1P54_01 308 55 244 134 317 41 80 36 151.9 9.8E-4 1.7E-2
V$NFY_01 1 559 42 157 106 242 30 92 153.6 1.1E-3 1.8E-2
V$COUP_DR1_Q6 86 67 194 232 269 223 62 97 153.8 1.1E-3 1.8E-2
V$NFY_C 73 135 35 539 245 86 47 90 156.3 1.2E-3 2.0E-2
V$AP4_Q6_01 60 228 79 459 250 57 75 91 162.4 1.7E-3 2.6E-2
CTCNANGTGNY_UNKNOWN 199 43 30 259 255 116 251 167 165.0 1.9E-3 3.0E-2
TMTCGCGANR_UNKNOWN 550 485 72 59 68 60 24 24 167.8 2.2E-3 3.3E-2
V$MYCMAX_B 22 510 271 276 234 4 36 34 173.4 2.9E-3 4.2E-2
YGCGYRCGC_UNKNOWN 67 267 249 491 160 88 41 28 173.9 2.9E-3 4.2E-2
V$AP2_Q3 78 58 91 544 279 96 111 137 174.3 3.0E-3 4.2E-2
CCAWNWWNNNGGC_UNKNOWN 39 256 222 203 360 153 100 93 178.3 3.5E-3 4.9E-2
Genes with common transcriptional regulatory sequence elements constitute a gene set. The ranking numbers indicate the ranking of each gene set 
out of a total of 761 gene sets in each data set and the mean ranking number indicate the ranking in the meta-analysis. Only 55 significantly up-
regulated out of a total of 761 gene sets are shown. No gene sets were significantly down-regulated. Ams: Amsterdam, Hua: Huang, HUM: 
HUMAC, Rot: Rotterdam, S03: Sotiriou 2003, S06: Sotiriou 2006, Sto: Stockholm, Upp: Uppsala.
BMC Cancer 2008, 8:394 http://www.biomedcentral.com/1471-2407/8/394with metastatic potential compared to non-metastatic
cells, is in agreement with some previously studies dem-
onstrating cell cycle as the major up-regulated pathway in
metastasizing breast cancer [5,10]. Up-regulation of
DNA_REPLICATION_REACTOME is required for cell
division and is sustained by both GSEA and GenMAPP.
Up-regulation of Purine and pyrimidine metabolism
pathways most likely also reflect elevated biosynthesis of
DNA, and pentose phosphate pathway serves to generate
ribose 5-phosphate that is a precursor in nucleotide syn-
thesis and NADPH that donates electrons for biosynthesis
of several molecules. Furthermore, pathways involved in
transcription (RNA_TRANSCRIPTION_REACTOME,
mRNA_PROCESSING_REACTOME) and translation
(AMINOACYL_TRNA_BIOSYNTHESIS) are up-regulated.
The crucial role of cell cycle and proliferation genes in
metastasis is strongly supported by several up-regulated
gene sets with recognition sites for E2F identified by motif
analysis (table 4). This family of transcription factors have
several targets involved in cell cycle e.g. cyclin E [16] and
expression of some E2F family members have been asso-
ciated with poor prognosis in breast carcinomas [17]. Fur-
thermore, NRF1 a transcription factor that co regulates a
large number of E2F target genes [18] and YY1 associated
with unchecked cellular proliferation [19] are also up-reg-
ulated according to the motif analysis.
1.2 Growth factors
Two growth factor pathways are down-regulated in
tumors with metastatic potential: Epidermal growth factor
(EGF) and platelet-derived growth factor (PDGF) path-
ways. This is surprising and one might expect the opposite
findings in cells with elevated proliferation. EGFR is
known to transmit mitogenic signals from EGF and TGFα
to several downstream signaling cascades: Phospholipase
C, RAS, phosphatidylinositol-3 kinase (PI-3K), and
STAT's. However, emerging evidence suggests an alterna-
tive mechanism that involves transport of activated EGFR
from the cell membrane to the nucleus and direct associ-
ation with gene promoters. Among the targets for nuclear
EGFR is cyclin D1 and iNOS [20]. The present results indi-
cate down-regulation of conventional mechanism which
might reflect activation of nuclear localization pathway.
The majority of genes in the EGF gene set are functioning
in the second messenger system while the nuclear locali-
zation pathway only involves EGFR. EGFR itself is not dif-
ferentially regulated (data not shown), but it might be
activated by other mechanisms. However, the activity of
the transcription factor ELK1 that is downstream target in
the conventional pathway is up-regulated according to
motif analysis indicating complex alterations of the EGF
pathway. Conflicting results have been reported for the
prognostic significance of EGF expression in breast cancer
(reviewed by Chan et al [21]).
PDGF signaling has previously been linked with breast
cancer metastasis in a mouse model. Furthermore,
increased expression of PDGFR and other key molecules
has been measured in invasive carcinomas compared to
intra ductal carcinomas and normal tissue [22]. This is
conflicting with present results showing overall down-reg-
ulation of PDGF pathway. The oncogene RAS which gene
product is activated by among others PDGF is however,
up-regulated in 5 of 7 data sets (data not shown). The
explanation for this discrepancy is unclear. The results
indicate differential expression of several genes between
metastasizing and non-metastasizing human breast
tumors, while other mechanisms may be present in mice
models and in the non-metastatic progression of tumors.
Other mechanism than the traditional signal transduction
pathways might also be involved. Furthermore, methodo-
logical problems for example in the definition of gene sets
may have impact. Other mechanisms than gene regula-
tion are surely involved in these pathways.
1.3 Metabolism
Several pathways involving basic energy metabolizing is
activated in metastasizing tumor cells: Glycolysis and gly-
coneogenesis, citric acid cycle, oxidative phosphorylation,
and electron transport chain. The pathway glycolysis and
glyconeogenesis cover presumably only glycolysis,
because glyconeogenesis is restricted to liver and certain
other organs. Glycolysis pathway converts glucose to
pyrovate which is subsequently decarboxylated in several
reactions in citric acid cycle, a pathway that is up-regu-
lated according to GenMAPP. NADH and FADH2, gener-
ated in citric acid cycle, contain electrons that are
transferred to molecular oxygen in electron transport
chain and oxidative phosphorylation. This results in gen-
eration of a proton gradient across mitochondrial inner
membrane, driving synthesis of ATP. Fructose and man-
nose metabolism pathway, up-regulated according to
GSEA, presumably cover the entry of fructose into glycol-
ysis by hexokinase, a general mechanism in adipose tis-
sue, where fructose level is high [23]. Hexokinase is
believed to be central for maintaining a high glycolytic
phenotype that characterizes cancer cells compared to
normal cells especially under conditions of hypoxia often
present in cancer cells [24]. This is supported by motif
analysis indicating activation of NFY and SP1 transcrip-
tion factors which has been shown to activate hexokinase
[25]. Furthermore, pathways generating energy from fatty
acid (fatty acid and clycerolipid metabolism) and amino
acids (valine, leucine, isoleucine, beta-alanine, and histi-
dine degradation) are down-regulated (GSEA).
These findings indicate that tumor cells with a metastatic
potential derive energy, to a higher extend, from carbohy-
drates and to a lesser extend fatty acids and amino acidsPage 7 of 12
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elevated synthesis and consumption of ATP appears to be
a feature of metastasizing tumor cells. Higher glucose
metabolism is also a characteristic of cancer cells, com-
pared to normal cells, used for detection of tumors and
metastases by PET scanning [26]. Glucose metabolism has
been hypothesized to improve survival of cancer cells
under hypoxia which is often observed in tumors [27].
Here we demonstrate prognostic disadvantage of higher
glucose metabolism in primary breast tumors. Further-
more, targets for the transcription factor hypoxia induci-
ble factor 1 (HIF1) is induced according to motif analysis,
strongly supporting the recent theory that HIF1 is an
inducer of glycolysis in response to hypoxia [27]. To our
knowledge no previous report has linked both elevated
glycolysis and decreased amino acid and fatty acid degra-
dation to breast cancer metastasis. Furthermore, the met-
abolic shift is reflected in many sustaining pathways
supporting the results.
1.4 Angiogenesis
Increased angiogenesis is believed to be an important
qualification for survival of breast cancer cells during
hypoxia often featuring breast tumors. Vasculature devel-
ops in response to growth factors like VEGF released by
the tumor. Furthermore, VEGF receptors on tumor cells
initiate a autocrine signaling response that facilitates sur-
vival in hypoxia and in response to other apoptotic stim-
uli [28]. This is supported by up-regulation of VEGF
pathway in present data sets. VEGF-inhibitors are being
tested as breast cancer drugs [29]. Furthermore, PPAR
pathway is down-regulated in metastasizing tumor cells.
PPARgamma is a ligand-activated transcription factor that
has been associated with decreased angiogenesis and inva-
siveness and with increased patient survival [30-32] in
agreement with present results.
1.5 Gleevec pathway
In chronic myelogenous leukemia (CML) the tyrosine
kinase ABL is often activated by a chromosomal transloca-
tion, t(9;22), resulting in fusion of BCR and ABL genes.
The kinase activity of ABL in the BCR-ABL fusion is acti-
vated and up-regulated; driving the uncontrolled cell
growth observed in CML. Gleevec is developed to inhibit
ABL and also inhibits the PDGF receptor tyrosine kinase
and the c-kit tyrosine kinase. The gene set included in the
present analysis only includes BCR-ABL pathway. Gleevec
has been introduced as anti-cancer drug not only against
cancer cells with BCR-ABL translocation, but also in some
cancers not having the translocation [33]. However, the
BCR-ABL and PDGF pathways inhibited by gleevec is
down-regulated in metastasizing tumors according to our
analysis, which might indicate that inhibition of ABL is
not relevant for treatment of breast cancer.
1.6 Migration
Mammalian cell motility requires actin polymerization in
the direction of movement to change membrane shape
and extend cytoplasma into lamellipodia. Migration is
believed to be central for primary tumor cells to reach
blood vessels or lymphatics in order to metastasize [34].
In agreement with this, we find actin pathway is up-regu-
lated in metastasizing tumors.
1.7 Signal transduction
S1P pathway is up-regulated according to GSEA. Sphingo-
sine-1 phosphate (S1P) is a lysolipid, acting via cell sur-
face coupled G-protein coupled receptors, and required
for migration, proliferation and survival of breast cancer
cells. Ectopic expression of the enzyme responsible for
S1P production, SphK1, increases tumorigenity and ang-
iogenesis and protect cell from apoptosis [35]. This sup-
ports our result, that increased expression of S1P pathway
members is involved in metastasis.
Several other signal transduction pathways are regulated.
The gene set GPCRDB_other, covers a group of G-protein
coupled receptors targeted by a broad range of ligands, is
down-regulated. Interleukin pathways (Il-3, Il-6, and Il-7)
are also down-regulated possibly indicating decreased
inflammatory response in metastasizing cells. Progester-
one signaling pathway (MPRPATHWAY) is increased and
ER transcriptional activity is enhanced according to motif
analysis confirming that elevated sex-hormone load may
lead to worse prognosis of breast cancer patients, which is
supported by the widely use and benefit of anti-hormonal
treatment of breast cancers retaining hormone receptors.
On the other hand nuclear hormone receptors
(NUCLEAR_RECEPTORS, table 2) theme self are down-
regulated in metastasizing tumors in agreement with loss
of ER and PgR as potent negative prognostic markers.
1.8 Proteasome pathway
Another pathway targeted for inhibitory treatment is pro-
teasome, a strategy that is supported by our finding that
the pathway is up-regulated in metastasizing tumors. Pro-
teasomes normally perform controlled degradation of
proteins and proteins selected for degradation by tagging
with a poly ubiquitin chain. In addition, proteasomes are
important regulators of several key regulatory proteins
including p53, cyclins, CDK inhibitors and NF-kB. The
proteasome inhibitor bortezomib has been suggested for
treatment of several cancers including breast [36].
1.9 Immune system
Immune function is also impaired; tollpathway, forming
part of innate immune system, is down-regulated in
metastasizing cells (table 2). Toll-like receptors (TLR) are
activated by pathogen expressed molecules and initiatePage 8 of 12
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cytokines. Activation of TLR's with synthetic agonists,
have shown promising results for treatment of several can-
cers, by inducing apoptosis and elevating sensitivity of to
cancer cells to chemotherapy [37,38]. The present results
may support this strategy in breast cancer [37].
1.10 DNA damage sensing and repair
ATRBRCA pathway is up-regulated in poor outcome
tumors. Several genes in this pathway are mutated in
hereditary breast cancer (BRCA1, BRCA2, ATM, p53, Fan-
coni anemia genes, and CHEK2) and the pathway is
believed to prevent cancer development by inducing cell
cycle arrest, DNA repair and apoptosis after DNA-damage
[39]. Up-regulation in metastatic cells may indicate a
compensatory mechanism or malfunction of this path-
way. Motif analysis indicate that BACH1, a transcription
factor that interacts directly with BRCA1, is up-regulated
[40]. Increased DNA repair has also been reported from
Wang et al when inspecting their prognostic classifier
genes [5].
2 Gene expression based pathway and transcription factor 
analysis
The present analysis of gene expression profiles of primary
tumors identifies several pathways associated to clinical
outcome. The identified pathway gene sets display signif-
icant imbalanced expression between metastasizing and
non-metastasizing breast tumors across several data sets.
This supports our hypotheses that several pathways are
involved in breast cancer metastasis and that they are
reflected in expression profiles of primary tumors. Fur-
thermore, motif analysis demonstrates many significantly
deregulated gene sets with common transcription factor
binding sites. The transcription factor binding sites are
identified by bioinformatics analysis and are for the most
part not functionally validated [13]. The finding that these
gene sets are significantly differentially expressed indi-
cates that the individual genes in the gene sets are actually
responding to the relevant transcription factors. Several of
the motif gene sets associated to metastasis have been
linked to certain pathways as discussed in the pathway
sections. Some of the transcription factors have also previ-
ously been linked directly to survival. A prominent exam-
ple is estrogen receptor targeted genes that are up-
regulated in metastasizing tumors. Another well known
transcription factor is Myc for which gene amplification is
associated to poor prognosis [41]. Also transcription fac-
tor YY1 has been associated with metastatic potential in
several cancers[19]. A number of predicted elements with
unknown transcriptions factors are present in promoters
of up-regulated genes. Further studies are needed to iden-
tify these factors and their functions. Interestingly, only
up-regulated gene sets are identified in motif analysis, in
agreement with our previous observation of a majority of
up-regulated genes in metastasizing breast tumors [1].
Predominance of up-regulated pathways with both GSEA
(26 out of 38 pathways) and GenMAPP (11 out of 19
pathways) meta-analysis supports this. The false discovery
rate used for correction for multiple testing is dependent
on the data structure and might bias this conclusion.
However, the imbalanced distribution of significant path-
way and motif gene sets is confirmed using Bonferroni
method (data not shown). No miRNA targeted gene sets
are identified in motif analysis which may reflect poor
algorithms for prediction of binding sites.
Different outcomes are used in the included studies:
relapse, metastasis, distant metastasis and death from
breast cancer. This may bias the results because relapse (3
data sets) includes local recurrences and these may be
result of suboptimal surgery or mechanism of spreading
different from distant metastasis. Regional metastasis, i.e.
recurrence in lymph nodes may also be the result of differ-
ent metastasis mechanism compared to distant metasta-
sis. However, local and regional recurrences constitute a
minor fraction of a typical tumor-bank cohort, resulting
in minor bias. To illustrate this, we examined a large Dan-
ish tumor-bank of primary tumors collected at Funen
from 1989 to 1999. Among patients that experienced
recurrences, 17% got local recurrence, 4% got regional
metastasis, and 79% got distant metastasis (data from
DBCG, http://www.dbcg.dk).
A varying fraction of the tumors in the individual data sets
have disseminated cells to the lymph nodes. Classification
of lymph node positive patients without recurrence as
non-metastasis may be controversial. This may bias the
results towards the metastatic mechanisms following pri-
mary spread to lymph node. Furthermore, a minor group
of included patients have received adjuvant treatment that
will bias the clinical outcome because a fraction of the
patients are responding to the therapy. One data set,
Huang, display conflicting results in pathway and motif
analysis (table 2, 3, 4). Noteworthy, the patients in this
study were all lymph node positive and received chemo-
therapy, which may explain the different results. Other
subgroups of tumors e.g. molecular subtypes are also
equalized by our approach resulting in identification of
general mechanisms involved in metastasis.
Overall, the included studies mainly contain lower risk
node negative untreated groups and the main outcome is
distant metastasis. The noise from other groups and out-
comes represented in the data sets may reduce the signifi-
cance of identified pathways. This actually means that our
statistical method is rather conservative. Furthermore, the
statistical test is even more conservative because only
ranking information from individual GSEA and Gen-
MAPP analyses are included. Using actual statisticalPage 9 of 12
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significance. However, due to the different distribution of
the parameters it was impossible to use them in meta-
analysis.
Few other studies have investigated biological mechanisms
in breast cancer gene expression data sets comparing meta-
static and non-metastatic outcome. The approaches that
have been used mainly concern the genes in outcome classi-
fiers (typically below 100 genes) often including a large frac-
tion of genes with unknown function. These studies have
mainly reported cell cycle, growth and proliferation to be up-
regulated, but some have reported angiogenesis, invasion
and signal transduction [10], while others have identified
cell death, DNA replication, recombination and repair genes
[5] or motility [11]. However, the concordance in these find-
ings besides cell cycle is low. We have in a previous study per-
formed meta-analysis of genes present in classifiers and
found cell cycle related gene ontology categories to be
strongly overrepresented, while other categories were not
present in more than one gene set [12]. Furthermore, classi-
fier genes are very dependent of classification algorithm, def-
inition of training and testing set, and many different
classifiers may result in same classification performance [42].
Yu et al. [43] recently performed pathway analysis of 500
gene signatures generated by re-sampling training sets from
the Rotterdam data set. In this way they minimized the bias
from definition of training set, however, they collected the
100 most significant genes each time, ignoring biological
mechanisms beyond the most strongly deregulated path-
ways.
Very different from this restricted approach this study utilizes
GSEA including all genes in data sets, offering the possibility
to reveal mechanism beyond cell cycle associated to metasta-
sis. Furthermore, meta-analysis identifies gene sets with
remarkably concordance between data sets. The findings are
strengthened by concordant findings with GenMAPP utiliz-
ing only the most significant genes. Compared to the over-
representation analysis often performed for classifiers,
GenMAPP includes app. 500 significant genes improving the
likelihood of identification of relevant biological functions.
Disagreement between the two programs for some gene sets
identified by one program but not the other may be
explained by the different algorithms. GenMAPP may tend
to ignore gene sets that are composed of genes with weak
individual contribution, while GSEA can give these a high
combined enrichment score if the fraction of these genes in
a gene set is high. Another explanation for discordant finding
is different definition of gene sets. Several GSEA gene sets are
adopted from GenMAPP, but there are several other contrib-
uters [15].
Sorlie at al. has also used global gene expression patterns
of large sample sets of breast tumors to investigate biolog-
ical mechanisms in breast cancer [44]. However, they used
a very different approach by performing unsupervised
clustering of samples to identify new subgroups that sub-
sequently were found to be associated with clinical out-
come. Their results point at different progenitor cell types
and estrogen and HER2 receptor status, but do not eluci-
date the different biochemical pathways involved in
metastasis. Very different from this, we have not aimed at
sub grouping tumors but instead intended to investigate
general metastatic pathways. Several pathways are also
supported by motif analysis indicating plausibly causal
explanation for observed gene expression differences.
Many of the identified pathways and transcription factor
have previously been identified with different focused
techniques. By our global approach we have validated
these findings. Furthermore, a number of new pathways
and transcription factors and promoter elements not pre-
vious linked to metastasis are identified. Further valida-
tion and functional testing is required to confirm their
role in metastasis.
Conclusion
By performing pathway meta-analysis, we have identified
several pathways involved in breast cancer metastasis.
Cancer is a genetic disease, and somatic mutations and
genomic instability are features of cancer development
and progression. In agreement with this, we find DNA
damage and repair pathway up-regulated in metastasizing
breast tumors. Uncontrolled cell cycle, a feature of cancer
cells compared to normal cells, also characterize meta-
static cells compared to non-metastatic cells. Growth fac-
tors are often hypothesized to play central role in cancer
proliferation and progression. We identify several changes
in growth factor pathways: PDGF and EGF pathways are
reduced, while signaling by VEGF, estrogen and progester-
one, is enhanced. The high proliferation rate in tumors
may lead to hypoxia, and in order for cancer cells to sur-
vive this, defense mechanisms are required and attraction
of blood delivery is central. Changed metabolism towards
glucolysis at expense of amino acids and lipids, help can-
cer cells to survive hypoxia, and angiogenesis improve
blood delivery thereby reducing hypoxia. Angiogenesis
also ensures a shorter distance for cells to the blood
stream, and enhanced migration is essential to cover this
distance. Immune system may protect against cancer pro-
gression supported by our finding that innate immune
system is impaired in metastasizing tumors. Finally, pro-
teasome pathway, an important regulator of proliferation
and apoptosis, is impaired.
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